2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia by Elizabeth Tkaczynski, Abinaya Arulselvan, John Tkaczynski,

Slides:



Advertisements
Similar presentations
An aptamer-based targeted delivery of miR-26a protects mice against chemotherapy toxicity while suppressing tumor growth by Toshihiko Tanno, Peng Zhang,
Advertisements

An anti-CD20–IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma by Stephen D. Gillies, Yan Lan, Steven Williams,
Monocytes form a vascular barrier and participate in vessel repair after brain injury by John Glod, David Kobiler, Martha Noel, Rajeth Koneru, Shoshana.
A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice by Brian D. Brown, Alessio Cantore, Andrea Annoni, Lucia Sergi Sergi,
Highly electronegative LDL from patients with ST-elevation myocardial infarction triggers platelet activation and aggregation by Hua-Chen Chan, Liang-Yin.
Platelet TGF-β1 deficiency decreases liver fibrosis in a mouse model of liver injury by Shahrouz Ghafoory, Rohan Varshney, Tyler Robison, Karim Kouzbari,
Downregulation of Antigen-Presenting Cell Functions After Administration of Mitogenic Anti-CD3 Monoclonal Antibodies in Mice by Eric Muraille, Fabienne.
by JoAnn Castelli, Elaine K
Hematopoietic cells regulate the angiogenic switch during tumorigenesis by Rika Okamoto, Masaya Ueno, Yoshihiro Yamada, Naoko Takahashi, Hideto Sano, Toshio.
PRT , a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model by Michael P. Reilly, Uma Sinha,
by Manuel Yepes, Maria Sandkvist, Mike K. K. Wong, Timothy A
In vivo retroviral gene transfer by direct intrafemoral injection results in correction of the SCID phenotype in Jak3 knock-out animals by Christine S.
Volume 21, Issue 10, Pages (October 2013)
by Rong Deng, and Joseph P. Balthasar
Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy by Mark P. Chao, Chad Tang, Russell K. Pachynski,
Cytosine-Phosphorothionate-Guanine Oligodeoxynucleotides Exacerbates Hemophagocytosis by Inducing Tumor Necrosis Factor–Alpha Production in Mice after.
Jacob Andrade, Shundi Ge, Goar Symbatyan, Michael S. Rosol, Arthur J
by Simon F. De Meyer, Alexander S. Savchenko, Michael S
Sympathetic stimulation facilitates thrombopoiesis by promoting megakaryocyte adhesion, migration, and proplatelet formation by Shilei Chen, Changhong.
IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation by Shirong Li, Jing Fu, Hui Wang, Huihui Ma, Xiaoming Xu, Yong-Guang.
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia by Lubica Rauova, Mortimer Poncz, Steven E.
Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of.
Lack of the adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerate the development of BCR/ABL-induced chronic myeloid leukemia-like.
Platelet-derived growth factor inhibits basic fibroblast growth factor angiogenic properties in vitro and in vivo through its α receptor by Francesco De.
Blocking LFA-1 Activation with Lovastatin Prevents Graft-versus-Host Disease in Mouse Bone Marrow Transplantation  Yang Wang, Dan Li, Dan Jones, Roland.
TLR5 signaling in murine bone marrow induces hematopoietic progenitor cell proliferation and aids survival from radiation by Benyue Zhang, Damilola Oyewole-Said,
Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.
The Synthetic Triterpenoid, CDDO, Suppresses Alloreactive T Cell Responses and Reduces Murine Early Acute Graft-versus-Host Disease Mortality  Kai Sun,
Jacob Andrade, Shundi Ge, Goar Symbatyan, Michael S. Rosol, Arthur J
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia by Zachary A. Hing, Rose Mantel,
Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease by Tangsheng Yi, Dongchang Zhao, Chia-Lei.
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation by Alexandra Mazharian, Cedric Ghevaert, Lin Zhang, Steffen Massberg,
Gastrointestinal microbiota contributes to the development of murine transfusion-related acute lung injury by Rick Kapur, Michael Kim, Johan Rebetz, Björn.
DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.
An aptamer-based targeted delivery of miR-26a protects mice against chemotherapy toxicity while suppressing tumor growth by Toshihiko Tanno, Peng Zhang,
PD-1 blockade enhances elotuzumab efficacy in mouse tumor models
Enhancing functional platelet release in vivo from in vitro–grown megakaryocytes using small molecule inhibitors by Danuta Jarocha, Karen K. Vo, Randolph.
A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b by Hua Zhou, Henrik Olsen, Edward So, Emmanuel.
T Cell–Mediated Rejection of Human CD34+ Cells Is Prevented by Costimulatory Blockade in a Xenograft Model  Annie L. Oh, Dolores Mahmud, Benedetta Nicolini,
Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice by Rikke Stagaard, Carsten Dan Ley, Kasper Almholt,
Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell–mediated remissions by Suparna Dutt, Michelle B. Atallah,
The effect of hyaluronan on CD44-mediated survival of normal and hydroxyl radical- damaged chondrocytes  P. Brun, Ph.D., S. Panfilo, B.S., D. Daga Gordini,
A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant by Shauna L. French, Claudia Thalmann, Paul F.
by Kamira Maharaj, John J
Volume 21, Issue 10, Pages (October 2013)
Juana Serrano-Lopez, Kalpana Nattamai, Nicholas A. Pease, Miranda S
Volume 22, Issue 1, Pages (January 2014)
Endogenous polyclonal anti–IL-1 antibody responses potentiate IL-1 activity during pathogenic inflammation  Gunther Spohn, PhD, Natalia Arenas-Ramirez,
by Kalpana Parvathaneni, and David W. Scott
by Sondra Downey-Kopyscinski, Ellen W
by Geling Li, Emily Waite, and Julie Wolfson
Platelet HMGB1 is required for efficient bacterial clearance in intra-abdominal bacterial sepsis in mice by Hui Zhou, Meihong Deng, Yingjie Liu, Chenxuan.
by Christina U. Lorentz, Norah G
Two distinct CXCR4 antagonists mobilize progenitor cells in mice by different mechanisms by Andia N. Redpath, Moïra François, Suet-Ping Wong, Dominique.
by Nicholas J. Laping, Michael P. DeMartino, Joshua E
The platelet NLRP3 inflammasome is upregulated in sickle cell disease via HMGB1/TLR4 and Bruton tyrosine kinase by Sebastian Vogel, Taruna Arora, Xunde.
Anti–protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis by Tamam Bakchoul, Heike Zöllner, Jean Amiral, Simon Panzer, Sixten.
Plasma biomarker concentrations between study groups.
Sibylle von Vietinghoff, Hui Ouyang, Klaus Ley  Kidney International 
by Kelly E. Johnson, Julia R. Ceglowski, Harvey G. Roweth, Jodi A
Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies by Nadine Müller-Calleja, Svenja.
FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice by Simone Merlin, Rosella Famà, Ester.
Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura by Liang Zheng, Yingying.
by Pamela J. Sung, Mayumi Sugita, Holly Koblish, Alexander E
Intratumoral platelet aggregate formation in a murine preclinical glioma model depends on podoplanin expression on tumor cells by Barbara Costa, Tanja.
Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.
Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea and weight loss. Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea.
How I treat heparin-induced thrombocytopenia and thrombosis
Endogenously produced n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in vivo. Endogenously produced n-3 PUFAs inhibit endometrial cancer.
DHA and dietary n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in xenograft models. DHA and dietary n-3 PUFAs inhibit endometrial cancer.
Presentation transcript:

2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia by Elizabeth Tkaczynski, Abinaya Arulselvan, John Tkaczynski, Stephen Avery, Liqing Xiao, Beverly Torok-Storb, Kraig Abrams, Narayanam V. Rao, Gregory Johnson, Thomas P. Kennedy, Mortimer Poncz, and Michele P. Lambert BloodAdv Volume 2(7):754-761 April 10, 2018 © 2018 by The American Society of Hematology

Elizabeth Tkaczynski et al. Blood Adv 2018;2:754-761 © 2018 by The American Society of Hematology

Chemical activity of ODSH Chemical activity of ODSH. (A) Chemical structure of the ODSH polysaccharide showing replacement of 2 sulfhydryl groups with hydroxyl groups at the 2-O and 3-O positions. Chemical activity of ODSH. (A) Chemical structure of the ODSH polysaccharide showing replacement of 2 sulfhydryl groups with hydroxyl groups at the 2-O and 3-O positions. (B) ELISA performed with an LRP1-coated plate showing dose-dependent inhibition of PF4 binding with increasing ODSH concentrations. (C) Uptake of PF4 by cultured megakaryocytes. N = 3 experiments performed in duplicate. P < .001 for PF4 vs PF4+ODSH for WT murine megakaryocytes, and P = .002 for PF4 vs PF4+ODSH for Cxcl4−/− murine megakaryocytes. Elizabeth Tkaczynski et al. Blood Adv 2018;2:754-761 © 2018 by The American Society of Hematology

In vitro anti-PF4 activity of heparin and ODSH In vitro anti-PF4 activity of heparin and ODSH. (A) Megakaryocyte colony assay showing the effect of PF4 (25 µg/mL) on colony formation and the effect of heparin (100 IU/mL). In vitro anti-PF4 activity of heparin and ODSH. (A) Megakaryocyte colony assay showing the effect of PF4 (25 µg/mL) on colony formation and the effect of heparin (100 IU/mL). N = 4 experiments performed in duplicate. *P = .01 compared with PF4. **P = .01 compared with control. (B) Same as panel A except for ODSH (100 µg/mL). N = 4 experiments performed in duplicate. **P < .001 vs control; *P < .001 vs PF4. (C) Liquid megakaryocyte culture of human CD34+ cells in the presence of PF4 (25 µg/mL) ± ODSH (100 µg/mL). N = 6 experiments performed in duplicate. *P < .01 vs PF4; **P < .001 vs control. Elizabeth Tkaczynski et al. Blood Adv 2018;2:754-761 © 2018 by The American Society of Hematology

ODSH effect on blood counts in CIT ODSH effect on blood counts in CIT. (A) Nadir platelet counts from mice shown in panel B demonstrating nadir platelet count was significantly higher in ODSH-treated mice vs control (P = .04) (N = 10 per arm). ODSH effect on blood counts in CIT. (A) Nadir platelet counts from mice shown in panel B demonstrating nadir platelet count was significantly higher in ODSH-treated mice vs control (P = .04) (N = 10 per arm). (B) Effect of ODSH SC injection starting 24 hours after administration of 5-FU in hPF4+/Cxcl4−/− mice (red circles, ODSH; blue circles, vehicle control) compared with Cxcl4−/− mice. Comparison of the curves showed the ODSH curve to be significantly different from the control curve; P < .04. Green circles represent WT animals examined simultaneously. Dashed line represents 100% baseline platelet count. N = 10 animals per arm. Elizabeth Tkaczynski et al. Blood Adv 2018;2:754-761 © 2018 by The American Society of Hematology

ODSH effect on blood counts in RIT in hPF4+ /Cxcl4−/−mice. ODSH effect on blood counts in RIT in hPF4+/Cxcl4−/−mice. (A) Nadir platelet counts of irradiated (6.5 Gy) hPF4+/Cxcl4−/− animals as percentage of baseline platelet count, which occurred at day 10 for ODSH-treated animals vs control Cxcl4−/− at day 12. P < .05. N = 20 animals per treatment arm. (B) Same as panel A but showing recovery of platelet count to baseline (dashed line demonstrates 100% baseline) after irradiation showing statistically different platelet counts starting at day 12 postirradiation (**P < .01 by Student t test after Bonferroni correction). N = 5 animals per arm. (C) Same as panel A, but showing survival of animals after irradiation, demonstrating improved survival in ODSH-treated animal (P < .04 by the Gehan-Breslow-Wilcoxon test). N = 20 animals per arm. (D) Same as panel A, but showing weight loss as percentage starting body weight for animals treated with ODSH or vehicle control. Dashed line is baseline body weight. N = 20 animals per arm. P < .001 for difference in curves. Elizabeth Tkaczynski et al. Blood Adv 2018;2:754-761 © 2018 by The American Society of Hematology

ODSH in RIT in WT animals. ODSH in RIT in WT animals. (A) Platelet counts of WT C57BL/6 animals as percentage of baseline platelet count after irradiation, showing statistically different platelet counts starting at day 8 postirradiation in animals treated with ODSH (25 mg/kg) starting 24 hours after irradiation and continuing for 3 doses every 12 hours. N = 15 animals per arm. P values by the Student t test after Bonferroni correction. (B) Same as panel A, but showing survival of irradiated animals. N = 15 animals per arm. P < .004 for survival difference by the Gehan-Breslow-Wilcoxon test. Elizabeth Tkaczynski et al. Blood Adv 2018;2:754-761 © 2018 by The American Society of Hematology

Effect of ODSH on intramedullary PF4 levels. Effect of ODSH on intramedullary PF4 levels. (A) hPF4+/Cxcl4−/− marrow 48 hours after irradiation stained with anti-hPF4 antibody. (B) Same as panel A, but for hPF4+/Cxcl4−/− marrow treated with a total of 75 mg/kg ODSH. (C) As in panel A, but for WT animal without irradiation. (D) As in panel B, but for WT animal treated with ODSH without irradiation. (E) Same as panel C, but 48 hours after irradiation in a WT animal (treated with PBS). (F) Same as panel D, but 48 hours after irradiation in a WT animal treated with ODSH. For all panels, scale bar = 100 µm; immunohistochemical stain and counterstained with hematoxylin. Elizabeth Tkaczynski et al. Blood Adv 2018;2:754-761 © 2018 by The American Society of Hematology